Focus: Plus Therapeutics is a public-stage radiotherapy-focused biotechnology company headquartered in Austin, TX, with a highly experimental pipeline spanning oncology, infectious diseases, and other therapeutic areas.
Profile data last refreshed 21h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Plus Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Help build intelligence for Plus Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Plus Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Plus Therapeutics secures FDA orphan drug status for pediatric glioma treatment - MSN
Plus Therapeutics secures FDA orphan drug status for pediatric glioma treatment MSN
Plus Therapeutics Inc (PSTV) Stock Price, Quote, News & History - Benzinga
Plus Therapeutics Inc (PSTV) Stock Price, Quote, News & History Benzinga
Indiana facility becomes second production site for CNS cancer drug - Stock Titan
Indiana facility becomes second production site for CNS cancer drug Stock Titan
Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™ - Yahoo Finance
Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™ Yahoo Finance
Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ - ChartMill
Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ ChartMill
Plus Therapeutics Inc Initiates Manufacturing Activities With SpectronRx Under A Master Services Agreement To Support GMP Pivotal Trial Readiness For REYOBIQ - marketscreener.com
Plus Therapeutics Inc Initiates Manufacturing Activities With SpectronRx Under A Master Services Agreement To Support GMP Pivotal Trial Readiness For REYOBIQ marketscreener.com
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
Multimodal evaluation of cerebrospinal fluid from breast cancer leptomeningeal metastases using circulating tumor cell detection, single-cell sequencing, and proteomics.
Convection enhanced delivery of Rhenium ((186)Re) Obisbemeda ((186)RNL) in recurrent glioma: a multicenter, single arm, phase 1 clinical trial.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo